Table 1.
Human tumor-derived cell lines of oral mucosa.
| Cell Line | Studies/Applications/Notes | References1 |
|---|---|---|
| BUCCAL CARCINOMA | ||
| TR146 | epithelial barrier studies, model cell line for human buccal epithelium (i.a. drug delivery, trans–epithelial permeability) model cell line for OSCC (i.a. cytotoxicity studies), C. albicans infection studies, 3D organotypic culture (i.a. in commercially available systems of reconstituted oral mucosa, e.g. SkinEthic Laboratories) |
62∏, 74#, 76, 78, 83, 94–97 barrier/permeability studies see also Table 3 >50 publications (“TR146”) |
| SqCC/Y1 | 3D organotypic culture, epigenetic studies, model cell line for malignant buccal carcinoma (i.a. in comparison to normal or immortalized keratinocytes such as SVpgC2a, see Table 3) |
98∏, 99–102, 103# >40 publications (“SqCC/Y1”) |
| HO-1-N-1 (Nakata-1; JCRB0831) | wound healing assays/migration, metastasis studies, investigation of retinoic acid (receptors) in OSCC |
104∏, 105–107#, 108,109 >10 publications (“HO-1-N-1”) |
| H413 (06092007 SIGMA) | P. gingivalis infection studies, epithelial barrier studies, epigenetic studies, TGFβ studies |
110∏, 111–114#, 115 barrier/permeability studies see also Table 3 >10 publications (“H413 oral”) |
| YD-9 | 1 out of 8 YD oral cancer cell lines (see 116), chemoresistant SCC model cell line, sensitivity to anticancer drugs, cancer-related over-expression studies |
116∏, 117–120# >10 publications (“YD-9” or “YD9) |
| OC3 | areca nut-chewing related buccal carcinoma cell line, cytotoxicity studies/tumor suppression |
121Л, 122,123#, 124,125 >10 publications (“OC3 oral”) |
| TW2.6 | areca nut-chewing and tobacco smoke-related buccal carcinoma cell line, tumor aggressiveness/migration/invasion studies, epigenetic studies |
126∏, 127#, 128–130 >10 publications (“TW2.6”) |
| TONGUE CARCINOMA | ||
| CAL27 | OSCC model cell line, cancer invasion/migration/metastasis/drug sensitivity studies, … |
131Л; recent publications: 132#, 133,134 >100 publications (“Cal27”) |
| CAL33 | OSCC model cell line, cancer invasion/migration/metastasis/drug sensitivity studies, … |
131Л, recent publications: 135–137 >40 publications (“Cal33”) |
| WSU-HN6 | cancer cell migration/motility/overexpression studies, drug sensitivity |
138Л, 139–141 >10 publications (“WSU-HN6”) |
| H357 (06092004 SIGMA) | OSCC model cell line for several cancer–related studies: drug sensitivity, cell migration, invasion, aggressiveness, … |
110Л; recent publications: 142–144 >40 publications (“H357 cancer”) |
| SCC25 (ATCC® CRL-1628™) | 1 out of 6 “SCC” cell lines, weakly invasive (see 145), OSCC model cell line for several cancer–related studies: drug sensitivity, signaling, migration, invasion, … |
145Л; recent publications: 133,146,147 ~>300 publications (“SCC25” or “SCC-25”) |
| D20 | moderate dysplastic cell line, 1 out of 16 dysplasias of the oral cavity (see 148), 3D organotypic culture of oral dysplasia |
148Л, 149–152# > 5 publications (“D20 dysplasia”) |
| DOK “dysplastic oral keratinocyte“ |
early and mild/moderate dysplastic cell line, tumor progression/migration studies, 3D organotypic culture of oral dysplasia, analysis of stemcell–associated markers |
153Л, 150,154–157# >15 publications (“DOK dysplastic”) |
| OSCC-BD “oral squamous cell carcinoma–B(a)P/DMBA” |
established from DOK by B(a)P/DMBA mixture (key carcinogens of tobacco smoke), identification of malignant transformation–related cancer proteins |
158∏ 1 publication (“OSCC-BD”) |
| HSC-3 (JCRB0623) | OSCC model cell line for several cancer–related studies: drug sensitivity, cell migration, invasion, aggressiveness, cell signaling, stem cell markers … |
159Л, recent publications: 160–162 ~>300 publications (“HSC-3 oral” or “HSC3 oral”) |
| HSC-4 (JCRB0624) | OSCC model cell line for several cancer–related studies: drug sensitivity, cell migration, invasion, aggressiveness, cell signaling, stem cell markers … |
163Л, recent publications: 160,164,165 ~>150 publications (“HSC-4 oral” or “HSC4 oral”) |
| OSC-19 | low-grade invasive cell model of epithelial phenotype, metastatic-lesion derived, metastasis studies, epigenetic studies, cytotoxicity studies, drug sensitivity studies, … |
166Л, 167–170# >50 publications (“OSC-19 oral” or “OSC19 oral”) |
| OSC-20 | low-grade invasive cell model of epithelial phenotype, metastatic-lesion derived, metastasis studies, cancer stem cell studies, … |
171Л, 168,170#,172 >20 publications (“OSC-20 oral” or “OSC20 oral”) |
| SCCKN | mouse xenograft cell model, cytotoxicity/drug sensitivity studies, … |
173Л, 174–176# >20 publications (“SCCKN”) |
| PE⁄CA-PJ15 | cytotoxicity/drug sensitivity studies, 3D organotypic culture, … | 177Л, 156,178–180# >15 publications (“SCCKN”) |
| YD-8 | 1 out of 8 YD oral cancer cell lines (see 116), SCC, cytotoxicity/drug sensitivity studies, … |
116Л, 181–183# >5 publications (“YD-8” or “YD8) |
| YD-10B | 1 out of 8 YD oral cancer cell lines (see 116), SCC, p53-mutant OSCC cell line, cytotoxicity/drug sensitivity studies, … |
116Л, 182, 183#, 184, 185 >20 publications (“YD-10B” or “YD10B) |
| YD-15 | 1 out of 8 YD oral cancer cell lines (see 116), mucoepidermoid carcinoma, cytotoxicity/drug sensitivity studies, … |
116Л, 186–188# >10 publications (“YD-15” or “YD15”) |
| SCC-4 (ATCC® CRL-1624) | OSCC model cell line, metastasis/migration studies, cytotoxicity/drug sensitivity studies, … |
189Л, recent publications: 190, 191# >100 publications (“SCC-4 oral” or “SCC4 oral”) |
| SCC-9 (ATCC® CRL-1629) | OSCC model cell line, metastasis/migration/invasion studies, overexpression studies, cytotoxicity/drug sensitivity studies, … |
145Л, recent publications: 192,193 >100 publications (“SCC-9 oral” or “SCC9 oral”) |
| SCC-15 (ATCC® CRL-1623) | OSCC model cell line, metastasis/migration/invasion studies, overexpression studies, cytotoxicity/drug sensitivity studies, … |
189Л, recent publications: 194,195# >100 publications (“SCC-15 oral” or “SCC15 oral”) |
| UMSCC2 | metastatic SCC cell line, cytotoxicity/drug sensitivity studies, mouse xenograft cell model |
196–198# >10 publications (“UMSCC2”) |
| SAS | cytotoxicity/drug sensitivity studies, cancer stem cell properties, migration/invasion studies, … | recent publications: 191Л, 199,200 ~>200 publications (“SAS oral carcinoma”) |
| GINGIVAL CARCINOMA | ||
| Ca9-22 | OSCC model cell line, cytotoxicity/drug sensitivity studies, epigenetic studies, cancer-related expression studies, … |
201Л, recent publications: 200,202 >200 publications (“Ca9-22”) |
| MSCC-1 | metastastic-lesion derived, metastasis/migration/invasion studies, |
203Л, 204 2 publications (“MSCC-1”) |
| KOSC-3 | invasion studies, mutational analysis |
205Л, 206–208# >5 publications (“KOSC-3” or “KOSC3”) |
| YD-38 | 1 out of 8 YD oral cancer cell lines (see 116), cytotoxicity/drug sensitivity studies, studies on tumor-associated macrophages |
116Л, 117,209,210# >10 publications (“YD-38” or “YD38”) |
| OEC-M1 | Metastasis/migration/invasion studies, cytotoxicity/drug sensitivity studies, cancer-, metastasis- related (over-)expression studies |
211Л, 213–215# >40 publications (“OEC-M1 oral” or “OECM1 oral”) |
| CARCINOMA OF THE FLOOR OF THE MOUTH | ||
| KOSC-2 | invasion studies, mutational analysis |
205Л, 206,207,215# >5 publications (“KOSC-2” or “KOSC2”) |
| POE-9n | severe dysplastic oral keratinocytes, not immortal but extended culture lifespan, 3D organotypic culture/tissue engineering, |
216Л, 150,156,217# >5 publications (“POE9n” or “POE-9n”) |
| HO-1-U-1 (Ueda 1; JCRB0828) | metastasis/invasion studies, epithelial barrier studies |
90Л, 91,93,165#, 218 >15 publications (“HO-1-U-1” or “HO1U1”) |
| H376 (06092005 SIGMA) | nanoparticle transport studies, cancer-related expression studies |
110Л, 219–221# >10 publications (“H376 oral”) |
| H314 (06092003 SIGMA) | cancer-related expression studies, TGFβ–related studies |
110Л, 222–224# >5 publications (“H314 oral”) |
| OTHERS (or not specified) | ||
| KB (ATCC CCL-17) epidermoid carcinoma ! cross - contaminated with HeLa cells! continued misrepresentation of KB cells as oral cancerphenotype (see 225) |
cancer-related (over-)expression studies, cytotoxicity/drug sensitivity studies, migration/metastasis/invasion studies … |
226Л, recent publications: 120,200,227 >300 publications (“KB epidermoid carcinoma oral”) |
| H400 (06092006 Sigma) alveolar process squamous cell carcinoma |
cytotoxicity/drug sensitivity studies, 3D organotypic culture |
110Л, 228–230# >10 publications (“H400 oral”) |
| MEMO oral mucosal melanoma cell line |
established from unusual case of oral mucosal melanoma on hard palate and maxillary alveolar ridge |
231∏ 1 publication, i.e. establishment (“MEMO melanoma”) |
| 1483/SCC1483 carcinoma of retromolar trigone region of the oropharynx some stocks genetically identical to UM-SCC1 (see 233) |
cancer-related expression studies, cytotoxicity/drug sensitivity studies |
233Л, 234–236 >10 publications (“1483 retromolar”) |
| FaDu hypopharyngeal squamous cell carcinoma |
migration/invasion studies, cytotoxicity/drug sensitivity studies |
237∏; recent publications: 238–240 >80 publications (“FaDu oral”) |
| BHY squamous cell carcinoma of lower alveolus |
cytotoxicity/drug sensitivity studies, cancer-related expression studies |
241Л, 242–244# >20 publications (“BHY oral”) |
| HSC-2 (JCRB0622) SCC of oral cavity |
OSCC model cell line, cytotoxicity/drug sensitivity studies, cancer-related (over-) expression studies, metastasis/migration/invasion studies, … |
163Л, recent publications: 165,199,245# >200 publications (“HSC-2 oral” or “HSC2 oral”) |
| HOC313 OSCC involving the mandibular gingiva and oral floor |
high-grade invasive cell model of mesenchymal phenotype, metastatic-lesion derived, cancer progression/metastasis/EMT studies |
246Л, 170#,247, 248# >20 publications (“HOC313”) |
| SCC Cell Line Collections | ||
| PCI cell lines | 21 HNSCC cell lines | 249Л |
| JHU cell lines (“John Hopkins University”) | 5 SCC cell lines of oral cavity: JHU-011 (larynx), −012 (oral cavity), −013 (oral cavity), −019 (base of tongue), −028 (unknown) | 250 |
| 73 UM-SCC (“University of Michigan Squamous Cell Carcinoma”) cell lines | 73 SCC cell lines of oral cavity | genotyping for all cell lines see 251 |
# … latest publication found using respective cell line
∏… publication describing establishment of respective cell line
1) References do not represent a complete list of publications, but list exemplary and/or latest studies. Approximate number of publications should give an impression of how often respective cell lines have been used previously. Search terms are given in parentheses.
abbreviations: HNSCC, head and neck squamous cell carcinoma; OSCC, oral squamous cell carcinoma; SCC, squamous cell carcinoma;